Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer

Histopathology

Volumn 58, Issue 7, 2011, Pages 1028-1036

  Braun, Martin ^a   Scheble, Veit J ^a   Menon, Roopika ^a   Scharf, Gregor ^a   Wilbertz, Theresia ^a   Petersen, Karen ^a   Beschorner, Christine ^a   Reischl, Markus ^b   Kuefer, Rainer ^c   Schilling, David ^a   Stenzl, Arnulf ^a   Kristiansen, Glen ^d   Rubin, Mark A ^e   Fend, Falko ^a   Perner, Sven ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ERG rearrangement; Gene fusions; Prostate cancer; TMPRSS2 ERG; Transition zone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG;

ARTICLE; BLADDER CANCER; COHORT ANALYSIS; CYSTECTOMY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TRANSURETHRAL RESECTION;

ADENOCARCINOMA; COHORT STUDIES; GENE FUSION; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; ONCOGENE PROTEINS, FUSION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RESEARCH DESIGN; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

EID: 79959759173     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03862.x     Document Type: Article

References (40)

1. Scheble VJ, Braun M, Beroukhim R et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod. Pathol. 2010; 23; 1061-1067.
2. Tomlins SA, Bjartell A, Chinnaiyan AM et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol. 2009; 56; 275-286.
3. Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod. Pathol. 2009; 22; 866-871.
4. Sieverding M, Matterne U, Ciccarello L, Luboldt HJ. Early detection of prostate cancer in Germany. A study of a representative random sample of the population. Urologe A 2008; 47; 1233-1238.
5. Perner S, Svensson MA, Hossain RR et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 2010; 75; 762-767.
6. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007; 70; 630-633.
7. Mehra R, Han B, Tomlins SA et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007; 67; 7991-7995.
8. Furusato B, Gao CL, Ravindranath L et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod. Pathol. 2008; 21; 67-75.
9. Scheble VJ, Braun M, Wilbertz T et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology 2010; 56; 937-943.
10. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310; 644-648.
11. Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66; 8337-8341.
12. Perner S, Mosquera JM, Demichelis F et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 2007; 31; 882-888.
13. Esgueva R, Perner S, J LaFargue C et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod. Pathol. 2010; 23; 539-546.
14. Pflueger D, Rickman DS, Sboner A et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009; 11; 804-811.
15. Mosquera JM, Mehra R, Regan MM et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin. Cancer Res. 2009; 15; 4706-4711.
16. Demichelis F, Fall K, Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26; 4596-4599.
17. Attard G, Clark J, Ambroisine L et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27; 253-263.
18. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008; 8; 497-511.
19. Mao X, Yu Y, Boyd LK et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010; 70; 5207-5212.
20. Noel EE, Ragavan N, Walsh MJ et al. Differential gene expression in the peripheral zone compared to the transition zone of the human prostate gland. Prostate Cancer Prostatic Dis. 2008; 11; 173-180.
21. King CR, Ferrari M, Brooks JD. Prognostic significance of prostate cancer originating from the transition zone. Urol. Oncol. 2009; 27; 592-597.
22. Sakai I, Harada K, Hara I, Eto H, Miyake H. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones. BJU Int. 2005; 96; 528-532.
23. Sakai I, Harada K, Kurahashi T, Yamanaka K, Hara I, Miyake H. Analysis of differences in clinicopathological features between prostate cancers located in the transition and peripheral zones. Int. J. Urol. 2006; 13; 368-372.
24. Greene DR, Wheeler TM. Clinical relevance of the individual prostate cancer focus. Cancer Invest. 1994; 12; 425-437.
25. Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J. Urol. 1991; 146; 1069-1076.
26. Noguchi M, Stamey TA, Neal JE, Yemoto CE. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J. Urol. 2000; 163; 1751-1755.
27. Shannon BA, McNeal JE, Cohen RJ. Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behaviour. Pathology 2003; 35; 467-471.
28. Falzarano SM, Navas M, Simmerman K et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod. Pathol. 2010; 23; 1499-1506.
29. Mehra R, Tomlins SA, Shen R et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 2007; 20; 538-544.
30. Rajput AB, Miller MA, De Luca A et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol. 2007; 60; 1238-1243.
31. Cheville JC, Karnes RJ, Therneau TM et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J. Clin. Oncol. 2008; 26; 3930-3936.
32. Nam RK, Sugar L, Wang Z et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. Ther. 2007; 6; 40-45.
33. Nam RK, Sugar L, Yang W et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br. J. Cancer 2007; 97; 1690-1695.
34. Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol. Ther. 2009; 8; 125-130.
35. Gopalan A, Leversha MA, Satagopan JM et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009; 69; 1400-1406.
36. Dai MJ, Chen LL, Zheng YB et al. Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer. Zhonghua Yi Xue Za Zhi 2008; 88; 669-673.
37. Rouzier C, Haudebourg J, Carpentier X et al. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet. Cytogenet. 2008; 183; 21-27.
38. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod. Pathol. 2007; 20; 921-928.
39. Yoshimoto M, Joshua AM, Chilton-Macneill S et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006; 8; 465-469.
40. Lapointe J, Kim YH, Miller MA et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod. Pathol. 2007; 20; 467-473.